Development of pharmacogenomics and individual therapy in cardiovascular and cerebrovascular drugs / 国际药学研究杂志

ABSTRACT

Cardiovascular and cerebrovascular diseases are world-wide threats to human health in recent years. Achievements in pharmacogenomics and individualized treatment have become a bright spot in the treatment of these diseases. Cardiovascular and cerebrovascular pharmacogenomic researches focus on the relationship between the drug effects and genetic polymorphism, which provide theoretical basis for individualized treatment. This review gives an overview of the developments of the pharmacogenomics of the most commonly therapeutic agents in the treatment of cardiovascular and cerebrovascular diseases, such as anticoagulants, antihypertensive agents, platelet aggregation inhibitors and cholesterol lowering drugs.